Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Some Math on HUGENESS of the OM Market

(as to size of potential cost savings)
(why a drug that can be shown to PREVENT OM will find a BIG market.. new S of C... in most if not all chemoradiated-treated cancers, not just HNC, where OM occurs)

# HNC cases (annual) = 65,000 (US only) (3-4% of all cancers)
x
Freq of SOM = 85% (FN1)
= 55,200
x $17,000 (incremental added cost of OM) (could be as high as $25,000 even as the $17k figure was a while back, 2011)

= $938,400,000 ($938m, or close to $1bn)

no wonder the SNGX CMO said (Bertolino himself couldn't have said it any better) the OM Mkt is all about Prevention

“The real goal in the whole Oral Mucositis arena is to try and prevent the development of this...”

R Straube SNGX CMO
(1m 15 secs in)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136846418

So: If B-OM can reduce S/OM by about 40% (per protocol) then we’re looking at around $400m in savings just in the U.S... think this wouldn’t make a compelling pitch to MCOs, PBMs? Then there is the stat that 25% of patients w S/OM have increased mortality due to interruptions in cancer treatment because the pain is so great... think patients and docs won’t want to Rx a simple swish/spit to increase odds by close to 40% at preventing?

Multiply the above #s by a factor of 10 -- the expected 700,000 HNC patients worldwide -- and you can an idea of just how big the oppty is in HNC ONLY. Then factor in that another 25-40% of all cancer patients (beyond HNC) get OM... and, well, the #s get really crazy really fast.

Looking fwd to seeing B-OM advance into a Ph3, hopefully under BTD, and under Partnership… and hope IPIX able to work in a healthy back-end (royalty split), less upfront if need be... cause if B-OM does get to market/s, the residual payments sure would be a nice boost to the rest of the pipeline – B IBD, B Derm, B ABSSSI, K oral, etc.

--

"New Developments in Management of Oral Mucositis in Patients With Head and Neck Cancer or Receiving Targeted Anticancer Therapies"

FN 1 As acknowledged by the ESMO clinical practice guidelines, the frequency of severe oral mucositis in patients undergoing therapy for head and neck cancer is high (the cumulative rate of grade 3 and grade 4 mucositis can be as high as 85%), and severe mucositis is a leading reason for treatment interruptions and chemotherapy dosage decreases.[2]